COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Chronic lymphocytic leukemia; Coronavirus infections; MortalityLeucemia linfocítica crónica; Infecciones por coronavirus; MortalidadLeucèmia limfocítica crònica; Infeccions per coronavirus; MortalitatPatients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007?1.038 and OR = 1.025, 95%CI 1.001?1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061?0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017-1.109 and OR = 2.438, 95%CI 1.023-5.813, respectively). Conclusions: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. METHODS: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. RESULTS: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR?=?1.022, 95%CI 1.007?1.038 and OR?=?1.025, 95%CI 1.001?1.051, respectively), while thromboprophylaxis use was protective (OR?=?0.199, 95%CI 0.061?0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR?=?1.062, 95%CI 1.017-1.109 and OR?=?2.438, 95%CI 1.023-5.813, respectively). CONCLUSIONS: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated

The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations

Attitudes and knowledge of Biodiversity of the university community

Proyecto de Innovación Docente 232 de la convocatoria 2019/2020. Se pretende conocer la actitud y los conocimientos generales de los usuarios del campus sobre la Biodiversidad, con el objetivo de mejorar la calidad docente en relación a ésta (proyectos ApS, asignaturas transversales y cursos relacionados).Teaching Innovation Project 232 of the 2019/2020 call. The aim is to know the attitude and general knowledge of campus users about Biodiversity, with the aim of improving teaching quality in relation to it (Service-Learning projects, cross-curricular subjects and related courses).Depto. de Biodiversidad, Ecología y EvoluciónFac. de Ciencias BiológicasFALSEsubmitte

El derecho de propiedad y el acceso a la vivienda ante un nuevo escenario inmobiliario: Retos y problemas. Libro de resúmenes del VI Congreso Iberoameriano de Derecho Inmobiliario

Resúmenes del VI Congreso Iberoamericano de Derecho Inmobiliario celebrado del 29 de septiembre al 1 de octubre de 2021 en Madrid organizado por la Cátedra UC3M - UCEN de Derecho Inmobiliario y la Universidad Francisco de Vitoria.Grabación de la primera jornada 29 septiembre 2021: https://www.youtube.com/watch?v=PD98tXgvMwI .-- Gabración de la segunda jornada 30 septiembre 2021: https://www.youtube.com/watch?v=Wo0dlkzHFQE . -- Grabación de la tercera jornada 1 octubre 2021: https://www.youtube.com/watch?v=hJigjXBB04YEl trabajo "La propiedad superficiaria, la propiedad temporal y la propiedad compartida como formas alternativas para la adquisición de vivienda" de Chantal Moll de Alba forma parte del Proyecto de investigación financiado por el Ministerio de Ciencia, Innovación y Universidades “Consumidor y vivienda: acceso, financiación y resolución de conflictos” (2019-2021) PGC2018-096260-B-C21.El fenómeno de la okupación en Chile / Francisco Javier Talep Pardo (p. 9). -- El Derecho Civil en la encrucijada: la progresiva influencia de los derechos fundamentales y humanos en la "okupación de viviendas" / Héctor Simón Moreno (p. 10- ). -- Ocupación y desahucios. Problemática procesal civil y propuestas de Lege Ferenda / Alejandro Fuentes-Lojo Ríus (p. 11). -- El papel del registro de la propiedad ante la "okupación" / José Blas Pau Echave-Sustaeta (p. 12). -- Régimen jurídico del suelo y expropiación en España / Antonio Descalzo González (pp. 14-15). -- Unicidad vs estanqueidad. La unicidad de valores como criterio justo y coherente en las valoraciones para la Administración: principio general de la buena fe / Antonio Eduardo Humero Martín (p. 16). -- La permuta real forzosa como medio indirecto de expropiación / Gilberto Mendoza de Maestro (p. 17). -- El tratamiento de la ocupación ilegal en la ejecución sobre bienes inmuebles: la experiencia española / Antonio Martínez Santos (p. 19). -- Límites a la propiedad inmobiliaria en las leyes sobre vivienda. (La función social de la vivienda) / Remedios Aranda Rodríguez (pp. 20-21). -- Propiedad, propiedades y su afectación por la función social / Mónica Muñoz-Alonso López (p. 22). -- Las comunidades de propietarios ante la ocupación ilegal de una vivienda / María Rosario Martín Briceño (p. 24). -- El fenómeno "okupa" y la vulneración de los derechos fundamentales / Carmen Iglesias Martín (pp. 25-26). -- Propiedad privada y derecho natural en la Escuela Kantiana / Jesús Miguel Santos Román (p. 27). -- La Administración Pública ante los casos de ocupación ilegal de inmuebles. Procedimientos de recuperación posesoria / Elena Sánchez Utrilla (p. 28). -- El alquiler social / Emilio Murcia Quintana (p. 31). -- Modelos de gestión de vivienda social en clave europea / Nuria Lambea Llop (p. 32). -- La protección del arrendamiento de vivienda y el registro de propiedad / Pilar Verdejo García (p. 33). -- La posesión sin título habilitante en el DL. 2695 de 1979 en Chile / Santiago Zárate González (p. 35). -- Diáspora habitacional en el entorno rural / Manuel Ignacio Feliú Rey (p. 36). -- La propiedad superficiaria, la propiedad temporal y la propiedad compartida como formas alternativas para la adquisición de vivienda / Chantal Moll de Alba (pp. 37-38). -- Soluciones habitacionales en derecho comparado / Ana María de la Encarnación (p. 39). -- El derecho de propiedad y vivienda: perfiles constitucionales legales / Ángel Juárez Torrejón (pp. 41-42). -- Medidas fiscales y vivienda: una perspectiva comparada / Sofía Borgia Sorrosal (p. 43). -- Creando un mercado para la eficiencia energética de los edificios: medidas tributarias de apoyo / Zulema Calderón Corredor (p. 44). -- El fideicomiso inmobiliario como instrumento para mitigar el déficit habitacional en Iberoamérica / Maridalia Rodríguez-Padilla (pp. 46-47). -- Fomento del alquiler residencial: medidas de incentivo y garantías al propietario arrendador / Beatriz Sáenz de Jubera Higuero (pp. 48-49). -- Derecho de propiedad y normativa urbanística en relación con el patrimonio arquitectónico rural andaluz / Elena Romero Cañabate y Gema Ramírez Pacheco (p. 50). -- Registro de la propiedad y nuevas tecnologías / Javier Gómez Gálligo (pp. 52-53). -- El documento electrónico notarial / Marco Antonio Sepúlveda Larroucau (p. 55). -- Tokenización y activos físicos inmobiliarios / Jesús Sieira y Jimena Campuzano (p. 56). -- La contratación inmobiliaria en plataformas / Teresa Rodríguez de las Heras Ballell (p. 57). -- La financiación de la actividad inmobiliaria a través de plataformas de crowdfunding inmobiliario / Teresa Asunción Jiménez París (p. 59). -- El fideicomiso como mecanismo para la mitigación de riesgo en el crowdfunding inmobiliario en México / Eduardo Rocha Núñez (p. 60). -- Transmisión propiedad inmobiliaria y nuevas tecnologías / María Goñi Rodríguez de Almeida (p. 62). -- La garantía funcional de los edificios inteligentes / Alejandro Zornoza Somolinos (p. 63). -- Ciudades inteligentes y la tributación al desarrollo / Diego Bisi Almada (p. 65). -- Blockchain y tokenización para la inversión inmobiliaria / Pedro Barreda García y Gema Ramírez Pacheco (p. 66). -- El futuro de la valoración inmobiliaria. Big data y modelos AVM / Andrea San José Cabrero (p. 67). -- Reflexiones sobre la contratación con plataformas digitales intermediarias en el sector inmobiliario / Pastora de Artíñano Marra (pp. 68)

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. METHODS: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. RESULTS: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007‒1.038 and OR = 1.025, 95%CI 1.001‒1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061‒0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017-1.109 and OR = 2.438, 95%CI 1.023-5.813, respectively). CONCLUSIONS: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

: In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations